Daix (France), Long Island City (New York, United States), Tokyo (Japan), September 20, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in clinical development orally administered small molecules for the treatment of non-alcoholic steatohepatitis and other diseases with an unmet medical need, and Hepalys Pharma, Inc., a company registered in Japan and incubated by Catalys Pacific, today announced an exclusive licensing agreement (the “Agreement”) to develop and commercialize Inventiva’s proprietary drug candidate lanifibranor for the treatment of NASH in Japan and South Korea.
Hepalys Pharma is a new company created by Catalys Pacific, an investment group specializing in the creation of companies and the financing of biopharmaceuticals through venture capital to develop pharmaceutical products in Asia. Hepalys Pharma is supported by renowned investors including Catalys Pacific, Mitsubishi UFJ Capital, DBJ Capital, and MEDIPAL Innovation Fund.
At the same time as the creation of Hepalys Pharma, Inventiva exercised its right to hold 30% of the company.